The syngo Virtual Cockpit platform reportedly enables remote access and image acquisition for CT, MRI and positron emission tomography (PET), and facilitates clinician collaboration across multiple sites.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the syngo Virtual Cockpit, a multi-vendor remote scanning platform that may help facilitate improved access to advanced imaging for patients in remote locations.
The syngo Virtual Cockpit enables remote access for computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET) and single-photon emission CT (SPECT) imaging, according to Siemens Healthineers, the manufacturer of the software. The company said the remote platform also features live video and chat functionalities to foster collaboration between clinicians across multiple sites.
In addition to possibly facilitating improved standardization for imaging of remote patients, Siemens Healthineers suggested the syngo Virtual Cockpit could be utilized in training staff at remote facilities.
“This FDA clearance means that our customers can use syngo Virtual Cockpit for their remote scanning operations with even more confidence that they are using a proven solution — one that prioritizes patient safety and convenience while also addressing operational and staffing challenges,” noted Peter Shen, head of digital and automation at Siemens Healthineers North America.
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Week, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
Multicenter CT Study Shows Benefits of Emerging Diagnostic Model for Clear Cell Renal Cell Carcinoma
May 15th 2024Combining clinical and CT features, adjunctive use of a classification and regression tree (CART) diagnostic model demonstrated AUCs for detecting clear cell renal cell carcinoma (ccRCC) that were 15 to 22 percent higher than unassisted radiologist assessments.
What a New Meta-Analysis Reveals About Fractional Flow Reserve Assessment with Computed Tomography
May 13th 2024While acknowledging variable accuracy overall with CT-derived fractional flow reserve (FFR-CT) values, researchers found that the accuracy rate increased to 90 percent for FFR-CT values greater > 0.90 and < 0.49.